Did the CDC Mislead Its Advisers on the RSV Antibody for Babies?
The seizure risk could apply to all RSV monoclonal antibodies now approved, potentially affecting millions of newborns. If the CDC presents safety data in a way that downplays clear signals of harm, the promise of a “reformed” advisory process collapses before it begins.
Did the CDC Mislead Its Advisers on the RSV Antibody for Babies? Read Journal Article











